| abstract |
Described herein are irreversible BTK inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of CNS malignancies. Specifically a method of treating a CNS malignancy in a subject comprising administering to said subject, a therapeutically effective amount of a BTK inhibitor of Formula (A1) is provided, wherein the preferred CNS malignancy is glioblastoma multiforme or CNS lymphoma. |